Empagliflozin in Patients with Chronic Kidney Disease
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index; 19 of the 28 sources its claims cite were checked for support.
Abstract
Trial of empagliflozin in a broad chronic kidney disease population.
Overview
CoChat Summary
TL;DR
Empagliflozin 10 mg daily reduced the risk of the composite of kidney disease progression or cardiovascular death in the EMPA-KIDNEY randomized trial of 6609 people with chronic kidney disease. Benefits were consistent with and without diabetes and across the eGFR range studied, with no clear increase in serious adverse events overall.
Key findings
- The primary composite outcome occurred in 432 of 3304 patients (13.1%) on empagliflozin versus 558 of 3305 (16.9%) on placebo; hazard ratio 0.72 (95% CI 0.64 to 0.82; P<0.001).
- All-cause hospitalizations were fewer with empagliflozin: 24.8 versus 29.2 hospitalizations per 100 patient-years; hazard ratio 0.86 (95% CI 0.78 to 0.95; P=0.003).
- There was no statistically significant effect on hospitalization for heart failure or cardiovascular death (4.0% vs 4.6%; hazard ratio 0.84, 95% CI 0.67 to 1.07; P=0.15) or death from any cause (4.5% vs 5.1%; hazard ratio 0.87, 95% CI 0.70 to 1.08; P=0.21).
- Empagliflozin slowed eGFR decline: the between-group difference in chronic slope was 1.37 ml/min/1.73 m² per year (95% CI 1.16 to 1.59), and urinary ACR was reduced by 19% (95% CI 15% to 23%).
Methods
- Multicenter, international, randomized, double-blind, placebo-controlled trial conducted at 241 centers in 8 countries; 6609 participants were randomized to empagliflozin 10 mg once daily or matching placebo.
- Eligible adults had CKD with eGFR ≥20 to <45 ml/min/1.73 m², or eGFR ≥45 to <90 ml/min/1.73 m² with urinary ACR ≥200 mg/g; patients with or without diabetes were eligible, and those with polycystic kidney disease or a kidney transplant were excluded.
- Primary analysis used intention-to-treat Cox regression adjusted for age, sex, prior diabetes, eGFR, urinary ACR, and region; key secondary outcomes were multiplicity-adjusted, and eGFR slope was assessed with shared parameter models.
Limitations
- The paper states that the lower-than-expected cardiovascular event rate reduced statistical power for secondary or tertiary cardiovascular outcomes.
- Evident from the text: the trial was stopped early for efficacy at an interim analysis, so follow-up was relatively short (median 2.0 years).
- Evident from the text: some subgroup estimates, especially for lower albuminuria strata, were limited by fewer primary outcome events.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
10 Valid · 0 Not valid · 4 Not checked · 40 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A prespecified subgroup analysis from a trial of the SGLT2 inhibitor dapagliflozin in patients with CKD and a urinary ACR of at least 200 mg/g, found that kidney benefits extended to patients without diabetes”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Conclusions
What the sources say
- Supportedcites [7] Heerspink HJL Stefansson BV Correa-Rotter R Dapagliflozin in Patients with Chronic Kidney Disease N Engl J Med 2020 383 15 1436 1446 10.1056/NEJMoa2024816 32970396 source
The Abstract (p. 1437) specifies a urinary albumin-to-creatinine ratio of 200–5000 mg/g. Figure 2 identifies diabetes status as a prespecified subgroup, and the Discussion states that kidney-protective effects extended to participants with chronic kidney disease without type 2 diabetes. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [12] Wheeler DC Stefansson BV Jongs N Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial Lancet Diabetes Endocrinol 2021 9 1 22 31 10.1016/S2213-8587(20)30369-7 33338413 source
- Supportedcites [13] Staplin N Roddick AJ Emberson J Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials EClinicalMedicine 2021 41 101163 10.1016/j.eclinm.2021.101163 34765951 PMC8571171 source
The Results (Eligible trial characteristics) identify DAPA-CKD as a dapagliflozin trial in patients with CKD and urinary ACR of 200–5000 mg/g. The Results (Relative effects of SGLT-2 inhibitors) report that the effect on kidney disease progression in the CKD trial appeared similar with and without diabetes; the References identify the underlying DAPA-CKD work as a prespecified analysis. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The effect of SGLT2 inhibition on kidney disease progression or cardiovascular death seen in the present trial is quantitatively similar to that seen in two other large placebo-controlled trials in CKD populations.6,7”
§ Empagliflozin in Patients with Chronic Kidney Disease > Discussion
What the sources say
- Supportedcites [6] Perkovic V Jardine MJ Neal B Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy N Engl J Med 2019 380 24 2295 2306 10.1056/NEJMoa1811744 30990260 source
The Methods identify CREDENCE as a placebo-controlled trial in patients with type 2 diabetes and albuminuric CKD. Table 2 reports a hazard ratio of 0.70 for its primary composite of kidney disease progression or renal or cardiovascular death. This supports the citation’s role as one of the two earlier CKD trials; the paper does not itself compare its result with EMPA-KIDNEY. (LLM, conf=0.88)
- Supportedcites [7] Heerspink HJL Stefansson BV Correa-Rotter R Dapagliflozin in Patients with Chronic Kidney Disease N Engl J Med 2020 383 15 1436 1446 10.1056/NEJMoa2024816 32970396 source
The Efficacy Outcomes table reports that DAPA-CKD was a placebo-controlled trial in patients with chronic kidney disease and found a lower risk of the kidney-progression or cardiovascular-death composite with dapagliflozin (hazard ratio, 0.61). The cited paper supplies one of the two trial results; the statement that its effect is quantitatively similar to EMPA-KIDNEY is the citing authors’ comparison, not a finding attributed to this paper alone. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“or death from any cause (4.5% vs 5.1%)”
- Also stated in: § Primary and Secondary Outcomes · plain
“or on death from any cause (hazard ratio, 0.87; 95% CI 0.70 to 1.08; P=0.21)”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Primary and Secondary Outcomes · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The rates of serious adverse events were broadly similar in the two groups.”
- Also stated in: § Safety Outcomes and Adverse Events · hedged
“There was no apparent evidence that empagliflozin increased the incidence of serious adverse events overall, or in any particular MedDRA system organ class (Table S8).”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Safety Outcomes and Adverse Events · hedged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were fewer hospitalizations from any cause in the empagliflozin group (0.86; 0.78 to 0.95, P=0.003)”
- Also stated in: § Primary and Secondary Outcomes · plain
“there were significantly fewer first and subsequent hospitalizations from any cause in the empagliflozin group (24.8 versus 29.2 hospitalizations per 100 patient years: hazard ratio, 0.86; 95% CI 0.78 to 0.95, P=0.003)”
- Also stated in: § Discussion · plain
“Risk of hospitalization for any cause was also reduced by 14%.”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Primary and Secondary Outcomes · plain
17 more claims
Create a free account to see all 54 claims and every source verdict.
- It may state two separate claims as one. 24
- Probably not a substantial claim. 16
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The empagliflozintreated participants had lower risk of progression of kidney disease and lower risk of death from cardiovascular causes (HR 0.72 [95% CI 0.64-0.82];P < 0.001).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [115]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The empagliflozin-treated participants had lower risk of progression of kidney disease and lower risk of death from cardiovascular causes (HR 0.72 [95% CI 0.64-0.82];P < 0.001).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [128]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Dedicated kidney outcomes trials in people with CKD and type 2 diabetes have shown that the SGLT2 inhibitors empagliflozin, canagliflozin, and dapagliflozin have beneficial effects on slowing progression of CKD and CV outcomes in this population (139-141).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [141]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, SGLT2i have been studied specifically among patients with CKD with or without T2D in 3 completed primary kidney outcome trials (CREDENCE[15], DAPA-CKD[16], and EMPA-KIDNEY[17]), which showed benefit for both a significant reduction in the primary kidney outcomes and cardiovascular outcomes [18,19].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“The DAPA-CKD and FIDELIO trials enrolled patients with eGFR ≥25 mL/min/1.73 m2 and the EMPA-KIDNEY trial enrolled patients with eGFR ≥20 mL/min/1.73 m2; results demonstrated that dapagliflozin, finerenone and empagliflozin are effective and safe in these patients, although safety data are lacking for initiating therapy below these thresholds [16,17,22].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [17]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493 · cited 1×
“…kidney disease with increased levels of albuminuria, large placebo-controlled trials have shown that renin-angiotensin system (RAS) inhibitors, 3–5 sodium-glucose cotransporter 2 (SGLT2) inhibitors, 6,7 and the non-steroidal mineralocorticoid receptor antagonist finerenone 8,9 all reduced the…”
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 2×
“6,7 The CREDENCE trial of canagliflozin required all participants to have type 2 diabetes and a urinary ACR of at least 300 mg/g, and excluded patients with an eGFR of less than 30 ml per minute per 1.73 m 2 .”
InfluentialLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618 · cited 3×
“…with an estimated GFR (eGFR) below 30 ml per minute per 1.73 m 2 or on how these benefits might vary among the wider range of patients with CKD. 7,12,13 This multicenter international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess…”
InfluentialThe effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Cited by
Items 301–400 of 2,656
SGLT2 inhibition for patients with ADPKD – closing the evidence gap
Müller, R., Guerrot, D., Chonchol, M., Schmitt, R., Uchiyama, K., Gansevoort, R. T., & Gall, É. C.-L. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf061 · Cited by 35
Pathophysiology and emerging biomarkers of cardiovascular-renal-hepato-metabolic syndrome
Nzobokela, J., Muchaili, L., Mwambungu, A., Masenga, S. K., & Kirabo, A. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1661563 · Cited by 44
Schechter, M., Wiviott, S. D., Raz, I., Goodrich, E. L., Rozenberg, A., Yanuv, I., Murphy, S. A., Zelniker, T. A., Fredriksson, M., Johansson, P. A., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00009-8 · Cited by 32
Battaglia, Y., Bulighin, F., Zerbinati, L., Vitturi, N., Marchi, G., & Carraro, G. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12113689 · Cited by 28
Llàcer, P., Romero, G., Trullàs, J. C., de la Espriella, R., Marcos, M. C., Quiroga, B., Casado, J., Slon-Roblero, M. F., Morales‐Rull, J. L., Morgado, J. I., et al. (2024) · Revista Española de Cardiología · doi:10.1016/j.recesp.2024.01.003 · Cited by 32
Erythrocytosis and CKD: A Review
Aoun, M., Jadoul, M. Y., & Anders, H. (2024) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2024.02.015 · Cited by 33
Drugs in Development to Treat IgA Nephropathy
Vecchio, L. D., Allinovi, M., Comolli, S., Peiti, S., Rimoldi, C., & Locatelli, F. (2024) · Drugs · doi:10.1007/s40265-024-02036-1 · Cited by 27
Jaiswal, V., Mashkoor, Y., Raj, N., Rajak, K., Jaiswal, A., & Fonarow, G. C. (2024) · The American Journal of Medicine · doi:10.1016/j.amjmed.2024.06.030 · Cited by 34
Mayne, K. J., Sardell, R. J., Staplin, N., Judge, P. K., Zhu, D., Sammons, E. L., Cherney, D. Z. I., Green, J. B., Levin, A., Pontremoli, R., et al. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae203 · Cited by 32
“The full methods of the EMPA-KIDNEY trial and the main re-sults have been reported elsewhere (ClinicalTrials.gov) [15 ].”
InfluentialSelf-citationFountoulakis, N., Miyamoto, Y., Pavkov, M. E., Karalliedde, J. J., & Maltese, G. (2024) · Diabetic Medicine · doi:10.1111/dme.15464 · Cited by 31
The prevention and management of chronic kidney disease among patients with metabolic syndrome
Zhu, D., Judge, P. K., Wanner, C., Haynes, R., & Herrington, W. G. (2025) · Kidney International · doi:10.1016/j.kint.2024.12.021 · Cited by 36
Tseng, P., Zeng, B., Hsu, C.-W., Hung, C., Carvalho, A. F., Stubbs, B., Chen, Y., Chen, T., Lei, W., Chen, J.-J., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04018-w · Cited by 36
Bozkurt, B., Rossignol, P., & Vassalotti, J. A. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3683 · Cited by 33
Cardiovascular, kidney, and metabolic health: an actionable vision for heart failure prevention
Ostrominski, J. W., CHENG, A. Y. Y., Nelson, A. J., Neuen, B. L., Sattar, N. A., Tuttle, K. R., & Vaduganathan, M. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01384-4 · Cited by 35
Chen, X., Wang, J., Lin, Y., Liu, Y., & Zhou, T. (2022) · Cells · doi:10.3390/cells11233913 · Cited by 29
Htoo, P. T., Tesfaye, H., Schneeweiß, S., Wexler, D. J., Everett, B. M., Glynn, R. J., Schmedt, N., Koeneman, L., Déruaz‐Luyet, A., Paik, J. M., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02150-0 · Cited by 31
“…composite kidney outcome (nephropathy including macroalbuminuria and ESKD) in patients with T2D and ASCVD, and a 28% risk reduction for kidney disease progression (ESKD) or cardiovascular mortality in patients with established CKD, consistently across subgroups defined by baseline eGFR [1, 3, 44].”
BackgroundTreatment and practical considerations of diabetic kidney disease
Bilen, Y., Almoushref, A., Alkwatli, K., Osman, O., Mehdi, A., & Sawaf, H. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1264497 · Cited by 29
Pragmatic Trial of Hospitalization Rate in Chronic Kidney Disease
Vazquez, M., Oliver, G., Amarasingham, R., Sundaram, V., Chan, K. T. K., Ahn, C. W., Zhang, S., Bickel, P. E., Parikh, S. M., Wells, B. L., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2311708 · Cited by 32
Tao, Y., Luo, R., Xiang, Y., Lei, M., Xuan, P., & Hu, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1342831 · Cited by 30
Kumar, N., Kumar, B., Ashique, S., Yasmin, S., Venkatesan, K., Islam, A., Ghosh, S., Sahu, A., Bhui, U., & Ansari, M. Y. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112050 · Cited by 29
Ferreira, J. P., Anker, S. D., Butler, J., Filippatos, G., Januzzi, J. L., Schueler, E., Panova‐Noeva, M., Wetzel, K., Prochaska, J. H., Pocock, S., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.03.503 · Cited by 34
Greco, A., Canale, M. L., Quagliariello, V., Oliva, S., Tedeschi, A., Inno, A., Biasio, M. D., Bisceglia, I., Tarantini, L., Maurea, N., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26104780 · Cited by 31
Staplin, N., Roddick, A., Neuen, B. L., Anker, S. D., Bhatt, D. L., Butler, J., Cherney, D. Z. I., Docherty, K. F., Fletcher, R. A., Inzucchi, S. E., et al. (2025) · JAMA · doi:10.1001/jama.2025.20835 · Cited by 41
Barratt, J., Lafayette, R. A., Rovin, B. H., & Fellström, B. (2023) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2023.2206119 · Cited by 27
Forbes, A., Suckling, R., Hinton, W., Feher, M. D., Banerjee, D., Cole, N. I., de Lusignan, S., & Swift, P. A. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15111 · Cited by 30
Peikert, A., Goyal, P., Vaduganathan, M., Claggett, B. L., Kulac, I. J., Miao, Z. M., Vardeny, O., Kosiborod, M., Desai, A. S., Jhund, P. S., et al. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.05.014 · Cited by 31
Posttransplant diabetes mellitus: recent developments in pharmacological management of hyperglycemia
Munoz Pena, J. M., & Cusi, K. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad395 · Cited by 24
Effects of Dapagliflozin in Chronic Kidney Disease Across the Spectrum of Age and by Sex
Yu, M., Vart, P., Jongs, N., Correa‐Rotter, R., Rossing, P. R., McMurray, J. J. V., Hou, F. F., Douthat, W., Khullar, D., Langkilde, A. M., et al. (2023) · Journal of General Internal Medicine · doi:10.1007/s11606-023-08397-9 · Cited by 35
Gan, T., Wang, Q., Song, Y., Shao, M., Zhao, Y., Guo, F., Wei, F., Fan, X., Zhang, W., Luo, Y., et al. (2023) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2023.112139 · Cited by 34
Safety and Tolerability of SGLT2 Inhibitors in Cardiac Amyloidosis—A Clinical Feasibility Study
Steinhardt, M., Cejka, V., Chen, M., Bäuerlein, S., Schäfer, J. M., Adrah, A., Ihne-Schubert, S. M., Papagianni, A. E., Kortüm, K. M., Morbach, C., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13010283 · Cited by 27
CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes
Schnell, O., Barnard-Kelly, K. D., Battelino, T., Ceriello, A., Larsson, H. E., Fernández‐Fernández, B., Forst, T. M., Frías, J. P., Gavin, J. R., Giorgino, F., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02180-8 · Cited by 29
“Until 2022, five and six CVOTs have been conducted for DPP-4is [11–15] and GLP-1 RAs [16–21], respectively, and five CVOTs [22–26], five HF [27–31] and three kidney [32–34] outcome trials with SGLT2is were published.”
BackgroundFinerenone in Persons with Chronic Kidney Disease without Diabetes
Heerspink, H. J. L., Neuen, B. L., Agarwal, R., Cherney, D. Z. I., Lam, C. S. P., Tuttle, K. R., Wanner, C., Sarafidis, P. A., Jongs, N., Smeijer, J. D., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2604625 · Cited by 71
Tanaka, T., Maruyama, S., Chishima, N., Akiyama, H., Shimamoto, K., Inokuchi, S., Yokota, K., & Ozaki, A. (2024) · Scientific Reports · doi:10.1038/s41598-024-55827-7 · Cited by 29
Sinha, F., Federlein, A., Biesold, A., Schwarzfischer, M., Krieger, K., Schweda, F., & Tauber, P. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1118358 · Cited by 27
“Abbreviations: CKD, Chronic kidney disease; EMPA, Empagliflozin; FITC, Fluorescein-isothiocyanate; GFR, Glomerular filtration rate; UNx, Unilateral nephrectomy.”
BackgroundInfluentialOda, Y., Nishi, H., & Nangaku, M. (2023) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2023.151431 · Cited by 30
Daprodustat and Heart Failure in CKD
Cunningham, J. W., Claggett, B. L., Lópes, R. D., McMurray, J. J. V., Perkovic, V., Carroll, K., Hiemstra, T. F., Khavandi, K., Lukas, M. A., Ranganathan, P. R., et al. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000321 · Cited by 24
Is There a Role for SGLT2 Inhibitors in Patients with End-Stage Kidney Disease?
Siddiqui, R., Obi, Y., Dossabhoy, N. R., & Shafi, T. (2024) · Current Hypertension Reports · doi:10.1007/s11906-024-01314-3 · Cited by 34
“The EMPA-KIDNEY trial also demonstrated that empagliflozin significantly reduced the risk of CKD progression or cardiovascular death across eGFR levels extending to stage 4 CKD [ 47 ].”
Tang, H., Donahoo, W. T., Svensson, M., Shaaban, C. E., Smith, G. E., Jaffee, M. S., Huang, Y., Hu, X., Lu, Y., Salloum, R. G., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14048 · Cited by 26
Treatment of Autosomal-Dominant Polycystic Kidney Disease
Jdiaa, S. S., Mustafa, R. A., & Yu, A. S. L. (2024) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2024.08.008 · Cited by 33
Bilson, J., Hydes, T., McDonnell, D., Buchanan, R. M., Scorletti, E., Mantovani, A., Targher, G., & Byrne, C. D. (2024) · Liver International · doi:10.1111/liv.16159 · Cited by 31
Liang, I.-C., Chang, H.-H., Lai, Y.-J., Chan, C.-M., Sung, C.-H., Pu, C., Chang, D., Ho, C.-C., & Hung, C. (2025) · Medicina · doi:10.3390/medicina61020202 · Cited by 28
Sodium-Glucose Cotransporter-2 Inhibitors and Arrhythmias
Jaiswal, V., Ang, S. P., Kumar, D., Deb, N., Jaiswal, A., Joshi, A., NASIR, Y. M., Bandyopadhyay, D., Michos, E. D., Benjamin, E. J., et al. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.101615 · Cited by 31
The Rapidly Changing Treatment Landscape of IgA Nephropathy
Cheung, C. K., & Barratt, J. (2024) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2025.151573 · Cited by 27
SGLT2 inhibitors as a novel senotherapeutic approach
Yeşilyurt, Z. E., Qi, C., Wang, Y.-C., Simm, A., Deelen, L., Gasim, A. H. A., Lewis, F., & Ellison, G. M. (2025) · npj Aging · doi:10.1038/s41514-025-00227-y · Cited by 33
Novel Cardiometabolic Medications in the Cardiovascular-Kidney-Metabolic Syndrome Era
Pohlman, N., Patel, P. N., Essien, U. R., Tang, J., & Joseph, J. J. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf295 · Cited by 28
Grams, M. E., & Melamed, M. L. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-02684 · Cited by 30
Lawrence, S. E., Chandran, M. M., Park, J. M., Sweiss, H., Jensen, T. B., Choksi, P. U., & Crowther, B. R. (2023) · Clinical Transplantation · doi:10.1111/ctr.14922 · Cited by 23
Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors and CKD: Are You a #Flozinator?
Krishnan, A., Shankar, M., Lerma, E. V., & Wiegley, N. (2023) · Kidney Medicine · doi:10.1016/j.xkme.2023.100608 · Cited by 28
Lupus Nephritis: New and Emerging Biologic and Targeted Therapies
Kale, A., Lech, M., Anders, H., & Gaikwad, A. B. (2023) · BioDrugs · doi:10.1007/s40259-023-00597-3 · Cited by 26
“Recently, the EMPA-KIDNEY trial demonstrated renoprotection in a mixed population of patients with CKD with or without diabetes (NCT03594110) [67].”
BackgroundChen, R., Zhang, H., Zhang, H., Zhou, H., Tong, W., Wu, Y., Ma, M., & Chen, Y. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175729 · Cited by 25
Fadini, G. P., Longato, E., Morieri, M. L., Bonora, E., Consoli, A., Fattor, B., Rigato, M., Turchi, F., Prato, S. D., Avogaro, A., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06251-z · Cited by 37
Li, X., Ma, T., Wang, M., Zhang, X., Liu, T., Liu, Y., Huang, Z.-H., Zhu, Y., Zhang, S., Li, Y., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1069348 · Cited by 27
“Current treatment strategies include 1) blood glucose control such as DPP-4 inhibitor linagliptin and SGLT-2 inhibitor empagliflozin (Srivastava et al., 2020a; Pugliese et al., 2020; Herrington et al., 2023), 2) blood pressure control such as Ang-II receptor blockers (ARBs) or angiotensin converting enzyme (ACE) inhib…”
MethodA systematic review on renal effects of SGLT2 inhibitors in rodent models of diabetic nephropathy
Ashfaq, A., Meineck, M., Pautz, A., Arioglu‐Inan, E., Weinmann‐Menke, J., & Michel, M. C. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108503 · Cited by 27
Bhanushali, K. B., Asnani, H., Nair, A. V., Ganatra, S., & Dani, S. S. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102664 · Cited by 28
Georgianos, P. I., Vaios, V., Koufakis, T., & Liakopoulos, V. (2024) · Drugs · doi:10.1007/s40265-024-02091-8 · Cited by 27
Cai, X., Cao, H., Wang, M., Yu, P., Liang, X., Liang, H., Xu, F. L., & Cai, M. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-025-05688-8 · Cited by 28
Update on the pathophysiology and treatment of diabetic kidney disease: a narrative review
Mima, A., Nomura, A., & Yasuzawa, T. (2025) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2025.2521086 · Cited by 30
“Recently, large clinical trials using sodium-glucose co-transporter 2 (SGLT2) inhibitors, such as empagliflozin (EMPA-REG Outcome, EMPA-KIDNEY) [8,9], canagliflozin (CREDENCE) [10], and dapagliflozin (DECLARE-TIMI 58, DAPA-CKD) [11,12], have been shown to significantly and clinically reduce the…”
2026 ESC Guidelines for the management of heart failure
Køber, L., Adamo, M., Ruwald, A., Tomasoni, D., Anderson, L., Andersson, C., Brugts, J. J., Chioncel, O. D., Donal, E., Ferdinandy, P., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag100 · Cited by 159
Maddaloni, E., Cavallari, I., Porta, Y. L., Appetecchia, A., D’Onofrio, L., Grigioni, F., Buzzetti, R., & Holman, R. R. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14986 · Cited by 28
Therapeutic Advances in Diabetic Kidney Disease
Georgianos, P. I., Vaios, V., Eleftheriadis, T., Papachristou, E. C., & Liakopoulos, V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032803 · Cited by 26
“73 m2, a sustained decline in the eGFR of ≥40% from the baseline, or death from renal causes) or death from cardiovascular causes [13].”
BackgroundInfluentialSanz, R. L., Inserra, F., Menéndez, S. G., Mazzei, L. J., Ferder, L., & Manucha, W. A. (2023) · Current Hypertension Reports · doi:10.1007/s11906-023-01240-w · Cited by 26
Sodium-Glucose Co-Transporters Family: Current Evidence, Clinical Applications and Perspectives
Nevola, R., Villani, A., Imbriani, S., Alfano, M., Criscuolo, L., Beccia, D., Ruocco, R., Femine, A. D., Gragnano, F., Cozzolino, D., et al. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2805103 · Cited by 26
Heerspink, H. J. L., Berger, S. P., Gansevoort, R. T., et al. (2023) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000221 · Cited by 22
Dapagliflozin in chronic kidney disease: cost-effectiveness beyond the DAPA-CKD trial
McEwan, P. C., Davis, J. A., Gabb, P. D., Wheeler, D. C., Rossing, P. R., Chertow, G. M., Correa‐Rotter, R., Tamura, K., Barone, S., & Sánchez, J. J. G. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae025 · Cited by 26
Focal Segmental Glomerulosclerosis
Suresh, V., Stillman, I. E., Campbell, K. N., & Meliambro, K. A. (2024) · Advances in Kidney Disease and Health · doi:10.1053/j.akdh.2024.03.009 · Cited by 44
The long-term effects of dapagliflozin in chronic kidney disease: a time-to-event analysis
McEwan, P. C., Gabb, P. D., Davis, J. A., Sánchez, J. J. G., Sjöström, C. D., Barone, S., Kashioulis, P., Ouwens, M., Cassimaty, S., Correa‐Rotter, R., et al. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae106 · Cited by 21
“…were included in the clinical trial to assess the efficacy and safety of empagliflozin in chronic kidney disease (EMPA-KIDNEY), demonstrating a 28% reduction in the primary composite outcome (progression of kidney disease or death from cardiovascular causes) over a 2.0-year follow-up period [27 ].”
InfluentialSchwalm, S. A., Manaila, R., Oftring, A., Schaefer, L., von Gunten, S., & Pfeilschifter, J. M. (2024) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-024-03029-5 · Cited by 24
The Effects of SGLT2 Inhibitors on Blood Pressure and Other Cardiometabolic Risk Factors
Katsimardou, A., Theofilis, P., Vordoni, A., Doumas, M. N., & Kalaitzidis, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212384 · Cited by 31
Rasalam, R. R., Sindone, A. P., Deed, G., Audehm, R. G., & Atherton, J. J. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15205 · Cited by 28
Agur, T., Steinmetz, T., Goldman, S. N., Zingerman, B. V., Bielopolski, D., Nesher, E., Fattal, I., Meisel, E., & Rozen‐Zvi, B. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02643-6 · Cited by 30
“While metformin has been associated with cardioprotective and nephroprotective effects, recent large-scale, high quality randomized controlled trials (RCTs) have highlighted the superior cardiovascular and renal benefits of SGLT2 inhibitors compared with all other treatments for T2D [31–35].”
Rashid, A. M., Khan, M. S., Cherney, D. Z. I., Mehta, A. N., Rangaswami, J., Shafi, T., & Butler, J. (2025) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000752 · Cited by 25
Ghafoury, R., Malek, M., Ismail‐Beigi, F., & Khamseh, M. E. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01743-6 · Cited by 31
Pathogenesis and Therapeutic Perspectives of Tubular Injury in Diabetic Kidney Disease: An Update
Geng, J., Ma, S., Tang, H. R., & Zhang, C. (2025) · Biomedicines · doi:10.3390/biomedicines13061424 · Cited by 31
Heerspink, H. J. L., Jongs, N., Neuen, B. L., Schloemer, P., Vaduganathan, M., Inker, L. A., Fletcher, R. A., Wheeler, D. C., Bakris, G. L., Greene, T., et al. (2023) · Kidney International · doi:10.1016/j.kint.2023.03.037 · Cited by 23
CKD therapy to improve outcomes of immune-mediated glomerular diseases
Anders, H., Juarez, G. M. F., Vaglio, A., Romagnani, P., & Floege, J. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad069 · Cited by 25
Cardiorenal syndrome and diabetes: an evil pairing
Méndez, A. B., Vergara, A., Olivella, A., Azancot, M. A., Soriano-Colomé, T., & Soler, M. J. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1185707 · Cited by 24
“Recently, several RCT such as CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation) (64), DAPA-CKD (Dapagliflozin in Patients with Chronic Kidney Disease) (65) and EMPA-KIDNEY (Empagliflozin in Patients with Chronic Kidney Disease) (66) have evaluated the renal outcome…”
BackgroundSGLT inhibitors for improving Healthspan and lifespan
O’Keefe, J. H., Weidling, R., O’Keefe, E. L., & Franco, W. G. (2023) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2023.10.003 · Cited by 27
Targeted identification of risk and treatment of diabetic kidney disease
Glastras, S. J., & Pollock, C. A. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-023-00796-9 · Cited by 24
Rodriguez‐Valadez, J. M., Tahsin, M., Masharani, U. B., Park, M., Hunink, M. G. M., Yeboah, J., Li, L., Weber, E. S., Berkalieva, A., Avezaat, L., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032463 · Cited by 22
Diabetic kidney disease: the kidney disease relevant to individuals with diabetes
Kanasaki, K., Ueki, K., & Nangaku, M. (2024) · Clinical and Experimental Nephrology · doi:10.1007/s10157-024-02537-z · Cited by 27
“…rate of decline in kidney function than did those in the positive group (ΔeGFR: macroalbuminuria ([ACR] ≥ 300 mg/g Cre) − 4.11 ml/min/1.73 m 2 /year, microalbuminuria group (300 > [ACR] ≥ 30 mg/g Cre) − 1.69 ml/min/1.73 m 2 /year, normal urinary albumin group − 0.89 ml/min/1.73 m 2 / year) [7].”
InfluentialKocabaş, U., Ergin, I., Yavuz, V., Altın, C., Kaplan, M., Öztekin, G. M. Y., Doğduş, M., Murat, S., Murat, B., Kıvrak, T., et al. (2024) · ESC Heart Failure · doi:10.1002/ehf2.15049 · Cited by 25
Advances in Chronic Kidney Disease in Africa
Rayner, B. L., Jones, E. S. W., Davidson, B. J., & Wearne, N. (2023) · Applied Sciences · doi:10.3390/app13084924 · Cited by 27
From Sweet to Sour: SGLT-2-Inhibitor-Induced Euglycemic Diabetic Ketoacidosis
Koceva, A., & Tramšek, N. A. K. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14070665 · Cited by 31
Community Point of Care Testing in Diagnosing and Managing Chronic Kidney Disease
Gama, R. M., Nebres, D., & Bramham, K. (2024) · Diagnostics · doi:10.3390/diagnostics14141542 · Cited by 29
Piperis, C., Marathonitis, A., Anastasiou, A., Theofilis, P., Mourouzis, K., Giannakodimos, A., Tryfou, E. S., Oikonomou, E. K., Siasos, G., & Tousoulis, D. (2024) · Biomedicines · doi:10.3390/biomedicines12102314 · Cited by 28
Ivashkin, V. T., Drapkina, O. M., Maevskaya, M. V., Raikhelson, K. L., Okovityi, S. V., Жаркова, М. С., Grechishnikova, V. R., Abdulganieva, D. I., Alekseenko, S. A., Ardatskaya, M. D., et al. (2025) · Russian Journal of Gastroenterology Hepatology Coloproctology · doi:10.22416/1382-4376-2025-35-1-94-152 · Cited by 31
Maintaining kidney health in aging societies: a JSN and ERA call to action
Ortíz, A., Kramer, A., Rychlík, I., Nangaku, M., Yanagita, M., Jager, K. J., Caskey, F. J., Stel, V. S., Kashihara, N., Kuragano, T., et al. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf068 · Cited by 25
“The mean age of participants in pivotal trials was > 60– 67 years and 16% were > 74–78 years of age, the range representing different trials [27 , 61 , 66 ].”
Advances in the treatment of ANCA-associated vasculitis
Trivioli, G., Moura, M. C., Kronbichler, A., Smith, R., Terrier, B., McAdoo, S. P., Jones, R. B., Merkel, P. A., & Jayne, D. R. W. (2025) · Nature Reviews Rheumatology · doi:10.1038/s41584-025-01266-1 · Cited by 28
“Sodium glucose cotransporter-2 inhibitors are now a mainstay in the treatment of CKD and are used in patients with AAV, although trials leading to approval of these drugs either excluded (the DAPA-CKD trial) or only included a small number of patients with AAV (the EMPA-KIDNEY trial) 196,197 .”
Hanke, J., Romejko, K., & Niemczyk, S. (2025) · Molecules · doi:10.3390/molecules30204125 · Cited by 35
Masuda, T., & Nagata, D. (2023) · Hypertension Research · doi:10.1038/s41440-023-01220-2 · Cited by 20
“the DAPA-CKD and EMPA-KIDNEY trials, among patients with CKD, regardless of the presence or absence of diabetes mellitus, the risk of a composite of a sustained decline in the estimated GFR, ESRD, or death from renal causes was significantly lower in patients treated with the SGLT2 inhibitors dapagliflozin or empaglif…”
BackgroundMüllens, W., Schulze, P. C., Westphal, J. G., Bogoviku, J., & Bauersachs, J. K. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad266 · Cited by 22
Castoldi, G., Carletti, R., Ippolito, S., Colzani, M., Pelucchi, S., Zerbini, G., Perseghin, G., Zatti, G., & Gioia, C. R. T. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310710 · Cited by 21
Emerging role of antidiabetic drugs in cardiorenal protection
Fu, W.-J., Huo, J., Mao, Z., Pan, S.-K., Liu, D., Liu, Z., Wu, P., & Gao, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1349069 · Cited by 24
An Updated Review of Membranous Nephropathy
Efe, O., So, P. N., Anandh, U., Lerma, E. V., & Wiegley, N. (2024) · Indian Journal of Nephrology · doi:10.25259/ijn_317_23 · Cited by 27
Modern Challenges in Type 2 Diabetes: Balancing New Medications with Multifactorial Care
Caturano, A., Galiero, R., Rocco, M. P., Tagliaferri, G., Piacevole, A., Nilo, D., Lorenzo, G. D., Sardu, C., Vetrano, E., Monda, M., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12092039 · Cited by 27
Reyes-Farias, C. I., Reategui-Diaz, M., Romani-Romani, F., & Prokop, L. (2023) · PLOS ONE · doi:10.1371/journal.pone.0295059 · Cited by 20
Management of Heart Failure in a Resource-Limited Setting: Expert Opinion from India
Jain, P., Guha, S., Kumar, S., Sawhney, J. P. S., Sharma, K. H., Sureshkumar, K. P., Mehta, A., Dhediya, R., Gaurav, K., Mittal, R., et al. (2024) · Cardiology and Therapy · doi:10.1007/s40119-024-00367-4 · Cited by 24
Wang, C.-A., Lin, L., Chen, J., Wang, W.-J., & Wu, V. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02424-7 · Cited by 25
“…reduce the risk of renal disease progression and death 1 Baseline characteristics between patients using SGLT-2is and non-users before and after propensity score matching from renal causes in patients with T2DM, as well as in those with CKD, regardless of their diabetes status [14, 41, 43].”
BackgroundChapman, F. A., Melville, V., Godden, E., Morrison, B., Bruce, L., Maguire, J. J., Davenport, A. P., Newby, D. E., & Dhaun, N. (2024) · Nature Communications · doi:10.1038/s41467-024-52447-7 · Cited by 25
The Dual Burden: Exploring Cardiovascular Complications in Chronic Kidney Disease
Caturano, A., Galiero, R., Rocco, M. P., Tagliaferri, G., Piacevole, A., Nilo, D., Lorenzo, G. D., Sardu, C., Russo, V., Vetrano, E., et al. (2024) · Biomolecules · doi:10.3390/biom14111393 · Cited by 36
Metadata
- Authors
- The EMPA-KIDNEY Collaborative Group
- Corresponding author
- The EMPA-KIDNEY Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-01-12
- Volume
- 388
- Issue
- 2
- Pages
- 117-127
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7614055
- OpenAlex
- W4308183941
- Cited by
- 2,754
- References
- 26
- Citations by year
- 2026: 727 · 2025: 759 · 2024: 734 · 2023: 520
- FWCI
- 321.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by-nd)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Docusalut (Conselleria de Salut i Consum del Govern de les Illes Balears) (submittedVersion, cc-by-nd)
- Hispana (submittedVersion, cc-by-nd)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Bristol Research (University of Bristol) (submittedVersion)
- Explore Bristol Research (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Funders
- Boehringer Ingelheim
- Eli Lilly and Company
- NIHR Biomedical Centre, Oxford
- Health Data Research
- Medical Research Council (MC_UU_00017/3 & MR/R007764/1)
- Kidney Research UK (MR/R007764/1)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- empagliflozin, chronic kidney disease, kidney disease progression, cardiovascular mortality, heart failure hospitalization, SGLT2 inhibitors, EMPA-KIDNEY trial, estimated glomerular filtration rate, diabetes mellitus
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Cardiovascular Diseases, Creatinine, Diabetes Mellitus, Type 2, Glomerular Filtration Rate, Glucosides, Humans, Kidney, Disease Progression, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.